Exemestane is a medicine used to treat breast cancer in women who have gone through menopause. It works by lowering the amount of estrogen in the body, which some breast cancers need to grow. It's taken as a pill once a day.
Every report comes from a Lived member, sent anonymously.
Have you tried Aromasin (Exemestane) for Breast Cancer?
Exemestane, sold under the brand name Aromasin and as a generic, is a daily tablet used to treat hormone receptor-positive breast cancer, the common type in which estrogen helps cancer cells grow. It belongs to a group of medicines called aromatase inhibitors, along with anastrozole (Arimidex) and letrozole (Femara). Its uses approved by the US Food and Drug Administration (FDA) are in women who have gone through menopause. After surgery for early breast cancer, a woman who has taken tamoxifen (another hormone-blocking pill) for two to three years can switch to exemestane to complete five years of hormone therapy, which lowers the chance of the cancer coming back. It is also approved for advanced breast cancer that has grown despite tamoxifen. Oncologists also use it in other ways supported by large trials and guidelines: as the first hormone pill after surgery instead of tamoxifen, where it works about as well as anastrozole; for longer courses, up to about ten years of hormone therapy in total for some higher-risk cancers; and to lower breast cancer risk in postmenopausal women at increased risk who have never had it. On its own, exemestane does not work before menopause, because the ovaries keep making estrogen. Premenopausal women receive it only together with ovarian suppression, injections or surgery that switch off the ovaries. In that combination it lowered the chance of recurrence more than tamoxifen did.
After menopause, the ovaries stop being the main source of estrogen. Instead, fat, muscle and other tissues make smaller amounts by converting androgens (hormones such as testosterone, made by the adrenal glands and ovaries) into estrogen, using an enzyme called aromatase. Exemestane is shaped like the hormone that aromatase normally converts. The enzyme takes it up and becomes permanently disabled, so the body has to make new enzyme. The result is a large drop in estrogen levels. Breast cancer cells that rely on estrogen lose that growth signal, which slows or stops their growth and makes it less likely that stray cancer cells left after surgery will grow into a recurrence. Because it is built like a steroid hormone, exemestane is called a steroidal aromatase inhibitor, unlike anastrozole and letrozole, and sometimes a person who stops responding to one type can still respond to the other.
The usual dose is one 25 mg tablet once a day, taken after a meal, which helps the body absorb it. Taking it at about the same time each day makes it easier to remember over a treatment that lasts years. People who also take certain medicines that speed up how the liver breaks exemestane down, such as rifampin or phenytoin, may be prescribed 50 mg a day instead. The brand and generic tablets contain the same medicine at the same strength.
The most common side effects come from lowering estrogen and feel like menopause symptoms: hot flashes, sweating, tiredness, trouble sleeping and headaches. Joint and muscle aches and stiffness are also common, often in the hands, knees and hips. These effects are a frequent reason people stop treatment early, so it is worth raising them with the care team. Exercise, other pain relief and sometimes switching to a different aromatase inhibitor can help. The most important longer-term effect is bone thinning. Exemestane gradually lowers bone density, which raises the risk of osteoporosis and broken bones over years of use. This is why bone health is monitored and, when needed, treated during therapy. In the main trial, heart problems caused by reduced blood flow, such as angina or heart attack, were slightly more common with exemestane than with tamoxifen (about 1.6% versus 0.6%). Chest pain or pressure, especially with shortness of breath or sweating, needs emergency care right away.
Estrogen-containing products, such as menopause hormone therapy or estrogen-containing birth control pills, should not be used with exemestane, because they work against its purpose of keeping estrogen low. Ask the oncologist before starting any hormone product, including vaginal estrogen. Some medicines speed up how the body clears exemestane and can make it less effective. They include rifampin (an antibiotic used for tuberculosis), the seizure medicines phenytoin, carbamazepine and phenobarbital, and the herbal supplement St. John's wort. The prescriber may raise the dose or choose another medicine, so tell the care team about all prescriptions and supplements. Exemestane can harm a developing baby. Anyone who could become pregnant, including premenopausal women taking it with ovarian suppression, should use effective birth control during treatment and for one month after the last dose, and should tell the care team right away about a known or suspected pregnancy. Breastfeeding is not recommended during treatment and for one month afterward.
Exemestane does not produce a change people can feel in the cancer itself. Its benefit is a lower chance that breast cancer returns or spreads, measured over years, or slower growth in advanced disease. For early breast cancer, hormone therapy usually continues for five years in total, and some people are advised to continue longer when their risk of recurrence is higher. The added benefit of longer treatment is modest and comes with more bone effects, so it is a shared decision. Before or soon after starting, the care team typically checks bone density with a DEXA scan (a low-dose X-ray of the hip and spine) and a vitamin D level, since low vitamin D is common in women with breast cancer. Calcium, vitamin D, exercise and, for some people, bone-strengthening medicines help protect the skeleton. Bone density is usually rechecked during treatment. Side effects often appear in the first months. Taking the tablet consistently matters, because stopping early lowers the protection it provides. If side effects make it hard to continue, talk with the oncologist about options rather than stopping on your own.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Aromasin (Exemestane), what you've noticed, or ask the community a question.